Loading...
OTCM
CTABF
Market cap0kUSD
Nov 19, Last price  
0.00USD
Name

Canntab Therapeutics Ltd

Chart & Performance

D1W1MN
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
144.95%
Revenues
293k
010,1570000026,667239,999133,3340293,362
Net income
-4m
L-16.53%
-100,406-1,451,777-1,557,322-301,241-178,532-173,840-1,116,252-2,408,413-2,458,578-2,607,244-4,419,782-3,689,186
CFO
-3m
L-0.13%
-55,416-1,074,810-1,310,884-520,851-30,141-257,503-354,807-1,268,748-2,333,058-1,899,427-2,849,478-2,845,899

Profile

Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
IPO date
Apr 21, 2011
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑052021‑052020‑052019‑052018‑052017‑052015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT